According to the latest report published by Credence Research, Inc. “Bronchitis Treatment Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global market for Bronchitis Treatment was valued at USD 3.345.8 million in 2017 and is expected to reach USD 4.606.3 million by 2026, increasing to CAGR by 4.9 percent from 2018 to 2026.
Market Insights
Bronchitis is one of the most common respiratory diseases seen in both developed and developing countries. Chronic bronchitis is life-threatening most of the time, and the Centers for Disease Control and Prevention reported that 8.6 million people were diagnosed with chronic bronchitis in the U.S. in 2016 with 0.2 percent mortality.
Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/bronchitis-treatment-market
However, as the U.S. is a more developed country, the mortality rate is low, but in developing and underdeveloped countries the mortality rate is between 3% and 4%. Bronchitis is caused by several common factors such as cold & flu, and other bacterial infections that lead to airway obstruction due to inflammation of the bronchial walls. Patients with acute bronchitis take 1 to 2 weeks to recover, while chronic bronchitis takes 2 to 3 months to recover. However, the overall drug treatment pipeline for bronchitis is strong due to the presence of several combination therapies that provide target-specific performance.
Bronchodilators were identified as the largest growing segment in the bronchitis treatment market in 2017 due to key factors such as increasing bronchitis-related prevalence and increasing awareness campaigns related to chronic bronchitis and other bacterial infections in developed and developing countries. The awareness-raising activities carried out in developing and developed countries have helped to increase the rate of diagnosis in the last few years. Bronchodilators are always the first-line drugs for the treatment of bronchitis, as clearing the airway obstruction is the most important thing in chronic bronchitis to ease the patient's breathing.
North America has been identified as the largest bronchitis treatment market due to rising prevalence coupled with high bronchitis prevalence, and an increasing trend in young people's smoking has contributed to a slight increase in prevalence, advanced and accessible diagnostic technologies. According to Pharmaprix, about 1 in 20 people in North America suffer from chronic bronchitis. In addition, the market for bronchitis in North America is also growing due to ongoing developments in research into the treatment of bronchitis by the drug pipeline.
Market Competition Assessment:
The bronchitis treatment market is growing at steadily and major companies operating in this market are developing treatments that are safe and target-specific. The major companies available in the global market are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.
Key Market Movements:
- Rising awareness and prevalence related to bronchitis treatment & diagnosis expected to assist the market growth
- Incessant growth in research & development of bronchitis treatment will assist the growth in demand for safe & efficient treatment options
- Mounting diagnosis rate related to developing countries will increase the demand for bronchitis treatment market
- Strong drug pipeline expected to increase the CAGR of the overall market in the near future
You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/59646
Key research study highlights comprise:
- Exhaustive research and analysis of the global bronchitis treatment industry
- The key market segments along have been explained in the report thoroughly along with their existing and estimated market size
- Major elements of market dynamics such as drivers, challenges and opportunities and their effect on bronchitis treatment market are also covered in the report
- Key players operating in the market are profiled and accompanied by the competitive landscape evaluated on the basis of product offering & business strength
- Cross-sectional analysis of each region covering individual segments for the forecast period 2018 - 2026 in terms of value (US$Mn)
The participants tracked for primary interviews include:
- Marketing/product managers
- Vice President/ CEOs
- National sales managers
- Market intelligence managers
- Distributors
- Purchasing man
Market Segmentation
By Type of Drug Class
- Antitussives/expectorants
- Bronchodilators
- Beta-adrenergic agonist
- Systemic corticosteroids
- Inhaled corticosteroids
- Phosphodiesterase-4 inhibitors
- Analgesics
- Antibiotics
By Pipeline Analysis
- Phase III
- Cyclosporine
- Combination Product: Extracorporeal Photopheresis (ECP)
By Geography Segment
- North America (the U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, Latin America)
No comments:
Post a Comment